Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies

Drugs and Aging

Volumn 25, Issue 8, 2008, Pages 707-714

  Burns, Alistair ^a   Yeates, Andrew ^b   Akintade, Latif ^c   Del Valle, Megan ^d   Zhang, Richard Y ^d   Schwam, Elias M ^d   Perdomo, Carlos A ^c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b EISAI CO LTD   (Japan)

^c EISAI INC   (United States)

^d PFIZER INC   (United States)

Author keywords

Alzheimer's disease, treatment; Donepezil, therapeutic use

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; PATIENT CODING; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; HUMANS; INDANS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 48249112245     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825080-00007     Document Type: Article

References (30)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7
2. Loy C, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database Syst Rev 2004; (4): CD001747
3. Birks J, Grimley EJ, Iakovidou V, et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000; (4): CD001191
4. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003; (3): CD001190
5. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006; (2): CD003154
6. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005; 331: 321-7
7. Pelosi AJ, McNulty SV, Jackson GA. Role of cholinesterase inhibitors in dementia care needs rethinking. BMJ 2006; 333: 491-3
8. Karlawish JH, Klocinski JL, Merz J, et al. Caregivers' preferences for the treatment of patients with Alzheimer's disease. Neurology 2000; 55: 1008-14
9. Farlow MR, Hake A, Messina J, et al. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 2001; 58: 417-22
10. Doraiswamy PM, Leon J, Cummings JL, et al. Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A Biol Sci Med Sci 2002; 57: M173-7
11. Butters MA, Lopez OL, Becker JT. Focal temporal lobe dysfunction in probable Alzheimer's disease predicts a slow rate of cognitive decline. Neurology 1996; 46: 687-92
12. Di Lazzaro V, Oliviero A, Pilato F, et al. Neurophysiological predictors of long term response to AChE inhibitors in AD patients. J Neurol Neurosurg Psychiatry 2005; 76: 1064-9
13. Adler G, Brassen S, Chwalek K, et al. Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 2004; 75: 292-4
14. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78
15. Tuite P, Riss J. Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs 2003; 12: 1335-52
16. Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 653-66
17. Lopez OL, Becker JT, Saxton J, et al. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005; 53: 83-7
18. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95
19. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303
20. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease: Donepezil Study Group. Neurology 1998; 50: 136-45
21. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31
22. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease: results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44
23. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000; 57: 94-9
24. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease: a 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group. Dement Geriatr Cogn Disord 2000; 11: 299-313
25. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-8
26. Gauthier S, Feldman H, Hecker J, et al. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 2002; 18: 347-54
27. Krishnan KR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-11
28. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-15
29. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63: 214-9
30. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004; 61: 1852-6